000K  utf8
1100  2023$c2023-09-30
1500  ger
2050  urn:nbn:de:hbz:465-20250108-110311-3
2051  10.1016/j.heliyon.2023.e20592
3000  Spetsotaki, Konstantina
3010  Kamler, Markus
3010  Koch, Achim
3010  Pizanis, Nikolaus
3010  Taube, Christian
3010  Theegarten, Dirk
4000  Incidence of malignancies after lung transplantation and their effect on the outcome$d26 years' experience  [Spetsotaki, Konstantina]
4209  Background: Malignancy is a significant, life-limiting complication after lung transplantation(LuTx) and the second common long-term cause of death. We aimed to investigate its incidence and effect on the outcome. Methods: This is a retrospective observational study. Between 1996 and 2022, n = 627 lung transplantations (LuTx) were performed in our department. We used our institutional database to identify recipients with malignancies after LuTx and examined the malignancies’ incidence and mortality. Results: N = 59 malignancies occurred in n = 55 (8.8%) LuTx recipients. The post-LTx malignancies incidence was 9.4% (59/627). We report the following rates based on their location: n = 17/55 (28,8% of all recipients diagnosed with malignancies) skin, n = 10/55 (16,95%) gastrointestinal, n = 9/55 (15,3%) respiratory, n = 5/55 (8,48%) lymphatic, n = 13/55 (23,6%) other, n = 5 (8,48%) multiple synchronous. During this study period, a total of n = 328 deaths after LuTx was determined. N = 29 (8,84% of all deaths) were malignancy induced, corresponding to a total malignancy-induced mortality of 4.6% (n = 29/627). The majority of deaths were attributed to GI adenocarcinoma and PTLD. Malignancies’ origin, primary COPD diagnosis, type, and specific age group were significantly survival-related (p-values <0.05). The most affected organ was skin and showed the best prognosis. PTLD had the fastest and pancreatic the latest onset. Conclusions: This is the first report of its kind in a large cohort of german LuTx recipients. The prevalence ranking of the three commonest malignancy were skin > colorectal > PTLD. Post-LTx malignancy was the second commonest cause of death. Further studies are needed, while post-LuTx malignomas remain a serious impairment of long-term LuTx survival.
4950  https://doi.org/10.1016/j.heliyon.2023.e20592$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:hbz:465-20250108-110311-3$xR$3Volltext$534
4961  https://duepublico2.uni-due.de/receive/duepublico_mods_00082267
5051  610
5550  Lung recipient
5550  Lung transplant
5550  Lung transplantation
5550  Malignancies
5550  Patient
5550  survival